康柏西普玻璃体腔注射治疗糖尿病视网膜病变伴黄斑水肿的临床效果

发布时间：2018-11-19 09:13

【摘要】：目的观察康柏西普玻璃体腔注射治疗糖尿病视网膜病变伴黄斑水肿的效果。方法选取糖尿病视网膜病变所致的黄斑水肿患者96例(96眼),随机分为观察组51例和对照组45例。观察组行玻璃体腔一次性注射康柏西普眼用注射液,对照组采用黄斑区格栅样光凝治疗。治疗前3 d及治疗1、7、14、28 d采用酶联免疫吸附法检测两组血清血管内皮生长因子(VEGF)水平,观察治疗前后黄斑形态、黄斑中心凹厚度、最佳矫正视力(BCVA)变化情况。结果与治疗前比较,观察组治疗1、7、14 d血清VEGF水平降低(P均0.05),治疗28 d恢复至治疗前水平。对照组治疗前后血清VEGF水平无变化。两组治疗后黄斑水肿明显改善,黄斑形态逐渐恢复正常,28 d时水肿基本消失,且观察组黄斑水肿消失情况优于对照组。治疗后7、14、28 d两组黄斑中心凹厚度较治疗前降低(P均0.05),且观察组低于对照组(P均0.05)。观察组治疗后6个月发生黄斑水肿复发、黄斑中心凹厚度增加。两组治疗后3、7、14、28 d BCVA逐渐提高(P均0.05),但治疗后6个月观察组视力又降至治疗前水平。结论康柏西普玻璃体腔一次性注射对于糖尿病视网膜病变伴黄斑水肿短期内有较好疗效,但其疗效持续时间较短。
[Abstract]:Objective to observe the effect of Corbeseptide intravitreal injection on diabetic retinopathy with macular edema. Methods 96 patients (96 eyes) with macular edema caused by diabetic retinopathy were randomly divided into observation group (n = 51) and control group (n = 45). The observation group was treated with a single injection of Corbeseptide ophthalmic injection into the vitreous cavity, while the control group was treated with macular area grid photocoagulation. The serum levels of vascular endothelial growth factor (VEGF) were measured by enzyme-linked immunosorbent assay (Elisa) 3 days before treatment and 28 days after treatment. The changes of macular morphology, macular fovea thickness and best corrected visual acuity (BCVA) were observed before and after treatment. Results compared with those before treatment, the serum VEGF level in the observation group was significantly lower than that in the control group on the 14th day after treatment (P 0.05), and recovered to the pre-treatment level on the 28th day after treatment. There was no change in serum VEGF level before and after treatment in the control group. After treatment, macular edema was obviously improved and macular morphology gradually returned to normal in both groups, and the edema disappeared basically at 28 days, and the disappearance of macular edema in the observation group was better than that in the control group. The thickness of macular fovea in both groups was lower than that before treatment (P 0.05), and the thickness of macular fovea in observation group was lower than that in control group (P 0.05). The macular edema recurred and the fovea thickness increased 6 months after treatment in the observation group. The BCVA of the two groups increased gradually on the 28th day after treatment (P < 0. 05), but the visual acuity of the observation group decreased to the level before treatment 6 months after treatment. Conclusion one-time injection of Compactopril into the vitreous cavity is effective in the treatment of diabetic retinopathy with macular edema in a short period of time.
【作者单位】：河北省眼科医院·河北省眼科学重点实验室;郑州大学第一附属医院;
【基金】：河北省科技厅基金资助项目(152777102D)
【分类号】：R587.2;R774

【相似文献】